<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858388</url>
  </required_header>
  <id_info>
    <org_study_id>OME01-2014</org_study_id>
    <nct_id>NCT02858388</nct_id>
  </id_info>
  <brief_title>Sinuclean Nebules 45 for Treatment of Pediatric Exudative Otitis Media</brief_title>
  <official_title>Safety and Efficacy of Sinuclean Nebules 45 (Class 1 Medical Device) in the Treatment of Pediatric Exudative Otitis Media, Randomized, Double Blind, Comparative, Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galsor S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galsor S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to investigate if the active agent of Sinuclean Nebules is&#xD;
      efficacious in the treatment of pediatric exudative otitis media, comparing with saline.&#xD;
&#xD;
      Sinuclean Nebules is a solution of cucurbitacins B,D,I,E (glycosylated triterpenes) 45 mcg,&#xD;
      extracted from Ecballium Elaterium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible pediatric subjects with diagnosis of mono or bi-lateral exudative otitis media&#xD;
      (obtained with otorhinolaryngologic endoscopic examination, tympanogram and tonal&#xD;
      audiometry), are randomized to treatment with Sinuclean Nebules 45 or saline.&#xD;
&#xD;
      Treatment is administered by trained caregiver with nebulizer (Rinowash Nasal Shower): one&#xD;
      nebulization/nostril/day for two cycles of 10 consecutive days. Cycles are interrupted by a&#xD;
      period of 7 days.&#xD;
&#xD;
      Visits 1 Baseline T0: confirmation of eligibility, randomization, training of caregiver,&#xD;
      dispensation of blinded therapy for two cycles, delivery of the clinical diary.&#xD;
&#xD;
      Visit 2 after 10 days of therapy + 7 days of interval: phone call to check for adverse&#xD;
      events, therapy adherence, concomitant diseases and treatments, and to prescribe second cycle&#xD;
      of therapy.&#xD;
&#xD;
      Visit 3 End of Study: assessment of the exudative otitis media with otorhinolaryngologic&#xD;
      endoscopic examination, tympanogram tonal audiometry, verification of the subject's clinical&#xD;
      diary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of tympanic effusion</measure>
    <time_frame>At Day 28 after start of treatment</time_frame>
    <description>The resolution of the tympanic effusion will be assessed with tympanogram (% of subjects with type A tympanogram).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete auditory recovery</measure>
    <time_frame>At Day 28 after start of treatment</time_frame>
    <description>The auditory recovery will be measured with tonal audiometry, % of subjects recovering normal values (threshold by air between 0 and 25 dB).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Otitis Media With Effusion</condition>
  <arm_group>
    <arm_group_label>SN45</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinuclean Nebules 45</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinuclean Nebules 45</intervention_name>
    <description>Nebulization of solution</description>
    <arm_group_label>SN45</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Nebulization of solution</description>
    <arm_group_label>Sal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of mono or bi-lateral exudative otitis media, performed the day&#xD;
             of recruitment or in the week before, with endotympanic effusion present for at least&#xD;
             3 months, and hearing loss.&#xD;
&#xD;
          -  The diagnostic criteria is type B tympanogram for at least one of the two ears.&#xD;
&#xD;
          -  The criteria is integrated by a) tonal audiometry to demonstrate bilateral or&#xD;
             monolateral deficit (loss of more than 20dB averaged to 0.5-1.2 and 4Khz in the best&#xD;
             ear with pure tone audiometry); for 1-3 yo subjects the audiometry is behavioural b)&#xD;
             otorhinolaryngologic examination in endoscopy for the otologic, rhino-sinusal and&#xD;
             pharyngeal districts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Outcomes of adenotonsillectomy&#xD;
&#xD;
          2. Velo-palatal insufficiencies, cleft lip and cleft palate.&#xD;
&#xD;
          3. Hearing loss of perceptual, and mixed type.&#xD;
&#xD;
          4. Clinical conditions (systemic diseases or other) that may interfere with the&#xD;
             evaluation of safety and clinical effectiveness of the product under investigation,&#xD;
             for example: diabetes mellitus, heart disease, chronic renal failure, active systemic&#xD;
             infections)&#xD;
&#xD;
          5. Assumption, during the study of drugs that may interfere with the assessment of the&#xD;
             product object of clinical investigation.&#xD;
&#xD;
          6. Possibility of needing treatment during the study with drugs that are not allowed, for&#xD;
             example: antibiotics in long-term prophylaxis, immunosuppressants, corticosteroids.&#xD;
&#xD;
          7. Regular intake of steroids in the four weeks preceding the date of the admission&#xD;
             visit.&#xD;
&#xD;
          8. Viral or allergic rhinitis, with active effusion.&#xD;
&#xD;
          9. Down Syndrome&#xD;
&#xD;
         10. Diagnosis of immotile cilia syndrome&#xD;
&#xD;
         11. Condition of immune deficiency disease or otherwise.&#xD;
&#xD;
         12. Cystic Fibrosis.&#xD;
&#xD;
         13. Dental malocclusion&#xD;
&#xD;
         14. Other diseases of other organ systems, which, in the opinion of the investigator, may&#xD;
             interfere with the purpose or the study procedures.&#xD;
&#xD;
         15. Not vaccinated subjects, with no clinical history of varicella who have been in&#xD;
             contact, in the 4 weeks before the admission visit, with people who may be suffering&#xD;
             from chicken pox or Zoster.&#xD;
&#xD;
         16. Psychic condition incompatible with participation in the research.&#xD;
&#xD;
         17. History of intolerance or allergy to the components of Sinuclean Nebules.&#xD;
&#xD;
         18. Medical and surgical intervention that may prejudice the complete execution of the&#xD;
             trial, in the 4 weeks preceding the signing of informed consent.&#xD;
&#xD;
         19. Imminence of a medical-surgical procedure that can jeopardize the completion of the&#xD;
             trial.&#xD;
&#xD;
         20. Participation in the course to other clinical investigations, or terminated within 30&#xD;
             days of the start of this trial.&#xD;
&#xD;
         21. Previous randomization in the study&#xD;
&#xD;
         22. Be first- or second-grade relative of a member of the Site study staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attilio Varricchio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Gennaro Hospital, Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Gennaro Hospital</name>
      <address>
        <city>Naples</city>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Zielhuis GA, Straatman H, Rach GH, van den Broek P. Analysis and presentation of data on the natural course of otitis media with effusion in children. Int J Epidemiol. 1990 Dec;19(4):1037-44.</citation>
    <PMID>2083987</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Otitis Media with Effusion</keyword>
  <keyword>Exudative otitis media</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Otitis Media with Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 3, 2016</submitted>
    <returned>November 22, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

